Background: Transcatheter aortic valve replacement (TAVR) is the method of choice in inoperable patients with severe aortic stenosis and is gaining increasing importance in high risk patients and intermediate risk patients with additional critical comorbidities or frailty. Two methods of access were used, transfemoral (TF) or transapical (TA), and baseline characteristics, clinical outcomes and mortality to three years were evaluated in both groups. Patient selection for TA or TF was made after consensus between interdisciplinary heart team members. All procedures were performed in a hybrid OR by a dedicated TAVR team. Methods: Group I: TA in 413 patients (SAPIEN THV: 402, Symetis Acurate: 11), Group II: TF in 587 patients (SAPIEN THV: 399, CoreValve: 188); from 5/08 to 04/12 in a single center heart team. Results: The mean age in TA group was 81.0 years and in TF 81.6 years, pϭ0.3. The TA group had more patients with peripheral artery disease (22.0% vs 10.9%), coronary artery disease (64.4% vs 58.3%), carotid stenosis (23.2% vs 15. 7%), redo-operation (25.7% vs 14.8%) and neurological dysfunction (14.8% vs 10.4%) than in TF (all pϽ0.05). In TF more patients were seen with pulmonary hypertension (22.0% vs 15.5%, pϽ0.05). The mean EuroSCORE I in TA was 24.2% and in TF 22.3% (pϭ0.007). Mortality at three years in TA was 33.7% and 27.3% in TF. Conclusions: With a dedicated, experienced heart team in a hybrid OR, patients with severe aortic stenosis can be treated with similar rates of mortality regardless of approach and despite the fact that one group has significantly more comorbidities. 
